Canada has implemented a policy allowing reliance on foreign regulatory decisions for certain drugs, enhancing approval efficiency and reducing duplication in evaluation processes.
Canada Streamlines Drug Approval via International Reliance
Manufacturers can now use foreign regulatory decisions to speed up domestic approvals.
What changed
Foreign regulatory reliance permitted for certain drug approvals, reducing duplicate evaluations.
WTO notification required for technical requirements on drugs and substances.
Product scope expanded to include hypertension medication, pain relievers, insulin, and other pharmaceuticals.
Who it affects
Drug manufacturers can leverage foreign approvals to enter Canadian market faster.
Pharmaceutical importers benefit from streamlined approval process for covered products.
Compliance Answer: Canada’s Policy on Reliance on Foreign Regulatory Decisions for Certain Drugs
Canada has implemented a risk-based reliance framework to streamline drug approvals by leveraging decisions or documents from specified foreign regulatory authorities (FRAs). This policy, established under the Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs (the Reliance Order), allows Health Canada to deem certain submission requirements met based on foreign evaluations, reducing duplication while maintaining safety and effectiveness standards1, 2.
Key Provisions of the Reliance Framework
The Reliance Order applies to specific classes of drugs identified on a list incorporated by reference (IbR List). To qualify for reliance, the following conditions must be met:
- Eligible Drug Classes
- The drug must belong to a class listed on the IbR List2.
- The list is dynamic and may be updated by Health Canada to reflect evolving regulatory priorities.
- Foreign Authorization
- The drug must have been authorized by an FRA included on the IbR List for the relevant drug class2.
- The FRA’s decision must be current and applicable to the submission in Canada.
- Safety and Effectiveness Alignment
- The manufacturer must demonstrate that any differences between the drug submitted in Canada and the version authorized by the FRA do not negatively impact safety or effectiveness2.
- This includes differences in formulation, labeling, or manufacturing processes.
- Submission Scenarios
The Reliance Order supports three submission pathways:
- General Deeming: For drugs already authorized by an FRA2.
- 120-Day Filing: Submissions filed in Canada within 120 days of filing with an FRA2.
- Joint Reviews: Submissions subject to collaborative review with one or more FRAs2.
- Resource Reallocation
- Health Canada may refocus resources on higher-risk areas, leveraging FRA expertise to improve efficiency2.
Regulatory Context and Objectives
1. Alignment with Red Tape Reduction (RTR)
The Reliance Order is part of Canada’s Red Tape Review (RTR), launched in July 2025, which aims to:
- Eliminate outdated regulatory barriers2.
- Align internationally to reduce trade barriers and expedite market access2.
- Support innovation by facilitating faster approvals for complex or novel therapies3.
2. Clinical Trials Modernization
While the Reliance Order focuses on drug approvals, Canada is concurrently modernizing its clinical trials framework under the Food and Drugs Act. Key changes include:
- Replacement of Part C, Division 5 of the Food and Drug Regulations (FDR) and Part 2 of the COVID-19 Clinical Trials Regulations with a standalone regulatory framework3.
- New requirements for good clinical practices, reporting, and oversight3.
- Entry into force: One year after publication in the Canada Gazette, Part II3.
3. Precursor Control Amendments (Unrelated but Concurrent)
For context, Canada has also amended the Precursor Control Regulations (PCR) and Schedule IX of the Controlled Drugs and Substances Act (CDSA) to combat illegal drug production (e.g., fentanyl). These changes:
- Expand oversight of precursor chemicals and designated devices (e.g., pill presses)4.
- Effective date: December 17, 2025, with a 6-month transition period for certain reporting requirements4.
Regulation Analysis
| Regulation | Key Requirement | Deadline/Threshold | Authority |
|---|---|---|---|
| Reliance Order | Drug must be on the IbR List and authorized by an FRA; differences must not impact safety/effectiveness2. | Not specified (ongoing) | Health Canada |
| 120-Day Filing Pathway | Submission must be filed in Canada within 120 days of filing with an FRA2. | 120-day window | Health Canada |
| Clinical Trials Regulations | Replaces existing clinical trial rules; establishes new authorization, reporting, and oversight requirements3. | Effective 1 year after publication in Canada Gazette, Part II3. | Health Canada |
| Precursor Control Regulations (PCR) Amendments | Mandatory reporting of suspicious transactions and employee training for Class A precursors4. | 6-month transition period post-publication (December 17, 2025)4. | Health Canada |
| Order Amending Schedule IX to the CDSA | Expands import registration requirements for designated devices (e.g., pill presses) and component parts4. | Effective December 17, 20254. | Health Canada |
Compliance Considerations
- Manufacturer Obligations
- Demonstrate equivalence: Manufacturers must provide evidence that the Canadian submission aligns with the FRA-authorized version, particularly for any differences in formulation, labeling, or manufacturing2.
- Timely filing: For the 120-Day Filing pathway, submissions must be filed in Canada within the specified window to qualify for reliance2.
- Health Canada’s Role
- International Collaboration
- The framework supports joint reviews and long-term regulatory convergence with FRAs, aligning with Canada’s commitment to international harmonization2.
- Stakeholder Engagement
- The comment period for the Reliance Order was extended to March 14, 2026, allowing industry and public input1.
Summary Answer
Canada’s Reliance Order enables manufacturers to leverage foreign regulatory decisions for certain drugs, reducing duplication in the approval process while maintaining safety and effectiveness standards. Key requirements include:
- The drug must belong to a class on the IbR List and be authorized by an eligible FRA2.
- Manufacturers must demonstrate that differences between the Canadian and foreign versions do not compromise safety or effectiveness2.
- Three submission pathways are available: General Deeming, 120-Day Filing, and Joint Reviews2.
- The policy aligns with Canada’s Red Tape Review (RTR) and broader efforts to modernize clinical trials and combat illegal drug production3, 4.
The Reliance Order is part of a risk-based approach to regulatory efficiency, allowing Health Canada to focus resources on higher-risk areas while expediting access to innovative therapies2. For related clinical trials modernization, the new standalone framework will replace existing regulations one year after publication in the Canada Gazette, Part II3.
Sources
- ↩ Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs — SS / directdoc https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN26/CAN765A1.pdf&Open=True
- ↩ Order Providing for Reliance on Decisions of, or Documents Produced by, Foreign Regulatory Authorities in Respect of Certain Drugs — SS / directdoc https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN26/CAN765.pdf&Open=True
- ↩ Committee on Technical Barriers to Trade – Notification – Canada – Drugs https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN26/CAN766.pdf&Open=True
- ↩ Committee on Technical Barriers to Trade – Notification – Canada – Drugs and substances https://docs.wto.org/dol2fe/Pages/SS/directdoc.aspx?filename=Q:/G/TBTN25/CAN761.pdf&Open=True